We report a case of minimal change disease presenting with AKI and nephrotic-range proteinuria 3 weeks after B-cell maturation antigen-directed CAR-T cell therapy, ciltacabtagene autoleucel, in a patient with relapsed refractory multiple myeloma. The patient received one dose of rituximab along with a short course of corticosteroid and had complete kidney recovery by week 4 of therapy. This report emphasizes the need for further investigation into the mechanism of kidney toxicity following CAR-T cell therapy, and potential benefits and risks of immunosuppressive therapy in this context.

P1, N=12, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting

P2, N=60, Not yet recruiting, Cartesian Therapeutics | Initiation date: Mar 2026 --> Jun 2026

P1/2, N=118, Recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd. | Phase classification: P1 --> P1/2 | N=18 --> 118

P1, N=52, Not yet recruiting, Washington University School of Medicine | N=40 --> 52

P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026

P1/2, N=182, Recruiting, AstraZeneca | N=80 --> 182

P1/2, N=17, Not yet recruiting, Nanjing IASO Biotechnology Co., Ltd.

P2, N=24, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

P1, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Not yet recruiting --> Recruiting

ORR was 75.4% (95% CI, 63.1-85.2) and CRR was 35.4% (95% CI, 23.9-48.2). The manufacturing success of ide-cel is reliable and consistently high, and when OOS ide-cel products emerged, they demonstrated consistent clinical efficacy and safety.

P2, N=6, Active, not recruiting, Cartesian Therapeutics | Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026